Staff Profile

I am a research fellow based in the Newcastle University Centre for Cancer. In my group we study the prostate tumour immune microenvironment. We focus on how glycans regulate the tumour immune microenvironment to drive immune suppression in prostate cancer. We are working to develop new therapies to target Siglec signalling and to understand how this will fit with current standard-of-care therapies.

For a full list of publications see Google Scholar: here

Glyco-immunology group members

Current members:

Adam Duxfield - Postdoctoral researcher (2024 - current)

Jamie Wills - MRC DiMeN PhD student (2024 - current)

Manuella Siaka Monthe - CRUK PhD student (2025 - current)

Previous members:

Dr Rebecca Garnham - PhD student and postdoctoral researcher (2020 - 2024)

Education and training

2020 Prostate Cancer UK Fellow - Biosciences Institute, Newcastle University

2019 Research Associate. Glycans as therapeutic targets and biomarkers for prostate cancer - Institute of Genetic Medicine, Newcastle University

2019 Ph.D. in Non-alcoholic fatty liver disease and hepatocellular carcinoma - Institute of Cellular Medicine, Newcastle University

2015 MBiolSci. Genetics - University of Liverpool

In our group we ask three key questions:

1) What are the regulators of tumour glyco-immunology?

2) How does glycosylation alter tumour immunology?

3) Can we target this axis to overcome immunotherapy resistance?

We address these questions through several key projects:

1) Understanding how AR-signalling alters glyco-immunology

2) Targeting Siglec immunoreceptors to modulate myeloid cell phenotypes in prostate cancer

3) Identifying regulators of macrophage glyco-immune checkpopints

4) Evaluating the contribution of stromal sialylation to prostate tumour immune suppression

5) Understanding how the liver microenvironment drives therapy resistance in metastatic prostate cancer

Teaching

UG and MRes project supervisor

Lecturer on BGM3065

Current PhD Supervision:

Primary supervisor

Jamie Wills 2024-2028

Manuella Siaka Monthe 2025-2029

Co-supervisor:

Holly Henderson 2024-2028

• Articles

  • Shaikh N, Teasdale M, Walker LJ, Wilson L, Howarth R, Saleem S, Logsdon J, Hepburn AC, Nelson R, Lian Q, Elizondo AC, Hussain R, Coxhead J, Gaughan L, Lako M, Scott E, Robson CN, Simons B, Hayward SW, Strand DW, Heer R, Buskin A. A xeno-free human iPSC-derived prostate organoid platform for multilineage differentiation and genetic manipulation. Cell Reports Methods 2026, 101538.
  • Bastian K, Orozco-Moreno M, Thomas H, Hodgson K, Visser EA, Rossing E, Pijnenborg JFA, Eerden N, Wilson L, Saravannan H, Hanley O, Grimsley G, Frame F, Peng Z, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Maitland NJ, Heer R, Wang N, Goddard-Borger ED, Guerrero RH, Boltje TJ, Drake RR, Scott E, Elliott DJ, Munkley J. FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors. Cancer Medicine 2025, 14(10), e70959.
  • Dalgliesh C, Aldalaqan S, Atallah C, Best A, Scott E, Ehrmann I, Merces G, Mannion J, Badurova B, Sandher R, Illing Y, Wirth B, Wells S, Codner G, Teboul L, Smith GR, Hedley A, Herbert M, de Rooij DG, Miles C, Reynard LN, Elliott DJ. An ultra-conserved poison exon in the Tra2b gene encoding a splicing activator is essential for male fertility and meiotic cell division. EMBO Journal 2025, 44, 877-902.
  • Hutton E, Uno Y, Scott E, Robson CN, Fascione M, Signoret N. A general and accessible approach to enrichment and characterisation of natural anti-Neu5Gc antibodies from human samples. RSC Chemical Biology 2025, 6(7), 1135-1147.
  • Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt EN, Walker L, Adamson B, Buskin A, Hepburn AC, Hodgson K, Kendall H, Frame FM, Maitland N, Coffey K, Strand DW, Robson CN, Elliott DJ, Heer R, Macauley M, Munkley J, Gaughan L, Leslie J, Scott E. ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. Communications Biology 2024, 7(1), 276.
  • Hodgson K, Orozco-Moreno M, Goode EA, Fisher M, Garnham R, Beatson R, Turner H, Livermore K, Zhou Y, Wilson L, Visser EA, Pijnenborg JF, Eerden N, Moons SJ, Rossing E, Hysenaj G, Krishna R, Peng Z, Nangkana KP, Schmidt EN, Duxfield A, Dennis EP, Heer R, Lawson MA, Macauley M, Elliott DJ, Bull C, Scott E, Boltje TJ, Drake RR, Wang N, Munkley J. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone. eBioMedicine 2024, 104, 105163.
  • Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, Marques FJG, Pye H, Yo EC, Islam K, Oo HZ, McClurg UL, Wilson L, Thomas H, Frame FM, Orozco-Moreno M, Bastian K, Arredondo HM, Roustan C, Gray MA, Kelly L, Tolson A, Mellor E, Hysenaj G, Goode EA, Garnham R, Duxfield A, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Bogdan D, Westaby D, Fowler G, Flohr P, Yuan W, Sharp A, de Bono J, Maitland NJ, Wisnovsky S, Bertozzi CR, Heer R, Guerrero RH, Daugaard M, Leivo J, Whitaker H, Pitteri S, Wang N, Elliott DJ, Schumann B, Munkley J. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene 2023, 42, 926–937.
  • Hodgson K, Orozco-Moreno M, Scott E, Garnham R, Livermore K, Thomas H, Zhou Y, He J, Bermudez A, Garcia Marques FJ, Bastian K, Hysenaj G, Archer Goode E, Heer R, Pitteri S, Wang N, Elliott DJ, Munkley J. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer. Scientific Reports 2023, 13(1), 17031.
  • Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, Livermore K, Putri Nangkana K, Frame FM, Bermudez A, Garcia Marques FJ, McClurg UL, Wilson L, Thomas H, Buskin A, Hepburn A, Duxfield A, Bastian K, Pye H, Arredondo HM, Hysenaj G, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Heer R, Maitland NJ, Whitaker H, Pitteri S, Troyer DA, Wang N, Elliott DJ, Drake RR, Munkley J. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. Journal of Pathology 2023, 261(1), 71-84.
  • Alebady ZAH, Azizyan M, Nakjang S, Lishman-Walker E, Al-Kharaif D, Walker S, Choo HX, Garnham R, Scott E, Johnson KL, Robson CN, Coffey K. CDC20 is regulated by the histone methyltransferase, KMT5A, in castration resistant prostate cancer. Cancers 2023, 15(14), 3597.
  • Scott E, Garnham R, Cheung K, Duxfield A, Elliott DJ, Munkley J. Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer. International Journal of Molecular Sciences 2022, 23(15), 8184.
  • Hall Z, Chiarugi D, Charidemou E, Leslie J, Scott E, Pelligrinet L, Allison M, Mocciaro G, Anstee QM, Evan GI, Hoare M, VidalPuig A, Oakley F, Vacca M, Griffin JL. Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma . Hepatology 2021, 73(3), 1028-1044.
  • Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, Oo HZ, Maia TM, Cheung K, Ehrmann I, Livermore KE, Zielinska H, Thompson O, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Daugaard M, Cockell S, Barbosa-Morais NL, Oltean S, Elliott DJ. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. eLife 2019, 8, e47678.
  • Govaere O, Petz M, Wouters J, Vandewynckel Y-P, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 2017, 36, 6605-6616.
  • Luukkonen PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, Hyotylainen T, Ali A, Juuti A, Leivonen M, Tukiainen T, Ahonen L, Scott E, Palmer JM, Arola J, Orho-Melander M, Vikman P, Anstee QM, Olkkonen VM, Oresic M, Groop L, Yki-Jarvinen H. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. Journal of Hepatology 2017, 67(1), 128-136.

• Reviews

  • Hutton E, Scott E, Robson CN, Signoret N, Fascione MA. A systematic review reveals conflicting evidence for the prevalence of antibodies against the sialic acid ‘xenoautoantigen’ Neu5Gc in humans and the need for a standardised approach to quantification. Frontiers in Molecular Biosciences 2024, 11, 1390711.
  • Advani R, Luzzi S, Scott E, Dalgliesh C, Weischenfeldt J, Munkley J, Elliott DJ. Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer. Oncogene 2023, 42, 3161–3168.
  • Buskin A, Scott E, Nelson R, Gaughan L, Robson CN, Heer R, Hepburn AC. Engineering prostate cancer in vitro: what does it take?. Oncogene 2023, 42, 2417–2427.
  • Scott E, Elliott DJ, Munkley J. Tumour associated glycans: A route to boost immunotherapy?. Clinica Chimica Acta 2020, 502, 167-173.
  • Garnham R, Scott E, Livermore KE, Munkley J. ST6GAL1: A key player in cancer (Review). Oncology Letters 2019, 18(2), 983-989.
  • Scott E, Munkley J. Glycans as Biomarkers in Prostate Cancer. International Journal of Molecular Sciences 2019, 20(6), 1389.